OncoResponse grabs $40 mln Series B
Houston, Texas-based OncoResponse, an immunotherapy company, has closed $40 million in Series B financing. RiverVest Venture Partners led the round.
11 September 2018•1 min read
Houston, Texas-based OncoResponse, an immunotherapy company, has closed $40 million in Series B financing. RiverVest Venture Partners led the round.
